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Simple Summary: Breast cancer is a leading cause of female cancer-related death worldwide. Anti-
HER2-targeted therapies dramatically improved prognosis for HER2-positive breast cancer patients.
Despite that, growing drug resistance due to the pressure of therapy is relatively frequent. For that
reason, it is necessary to find biomarkers able to predict treatment sensitivity and survival outcomes.
Increasing research has shown how miRNAs, secreted by tumor cells, are strongly involved in cancer
development. In this review, we will discuss the recent evidence on the predictive and prognostic
value of miRNAs involved in HER2-positive early breast cancer progression.
Abstract: MicroRNAs (miRNA) are small noncoding RNAs that can act as both oncogene and tumor
suppressors. Deregulated miRNA expression has been detected in human cancers, including breast
cancer (BC). Considering their important roles in tumorigenesis, miRNAs have been investigated
as potential prognostic and diagnostic biomarkers. Neoadjuvant setting is an optimal model to
investigate in vivo the mechanism of treatment resistance. In the management of human epidermal
growth factor receptor-2 (HER2)-positive early BC, the anti-HER2-targeted therapies have drastically
changed the survival outcomes. Despite this, growing drug resistance due to the pressure of therapy is
relatively frequent. In the present review, we focused on the main miRNAs involved in HER2-positive
BC tumorigenesis and discussed the recent evidence on their predictive and prognostic value.
Keywords: exosome; miRNA; extracellular vesicles; HER2 positive breast cancer; early stage breast
cancer; neoadjuvant chemotherapy; trastuzumab; predictive factors; prognostic factors
1. Introduction
Breast cancer (BC) is the most common type of cancer diagnosed in women worldwide,
with around 2.3 million new cases in 2020 and 685,000 deaths globally according to the
World Health Organization [1]. The human epidermal growth factor receptor-2 (HER2)
is overexpressed in almost 20% of cases and is generally associated with poorer survival
outcomes [2]. Thanks to the advent of anti-HER2-targeted therapies, prognosis for HER2-
positive BC patients has dramatically improved [3–12]. Despite their objective activity,
intrinsic and acquired resistance to anti-HER2 agents remains a major clinical challenge [13].
To address this problem of resistance, considerable efforts have been made to investigate
Cancers 2021, 13, 4894. https://doi.org/10.3390/cancers13194894 https://www.mdpi.com/journal/cancers
Cancers 2021, 13, 4894 2 of 13
the mechanism of treatment failure. The neoadjuvant setting is an optimal model for
studying in vivo the mechanism of treatment resistance [14,15].
Growing evidence has indicated that microRNA (miRNA) profiling could be a promis-
ing biomarker for early diagnosis, treatment sensitivity/resistance, and prognosis in differ-
ent cancer types, including BC [16–18]. MiRNAs are a class of small noncoding regulatory
RNAs that are involved in both physiological and pathological processes, such as cancer
proliferation [19]. miRNAs can be easily detected in blood and tumor tissue [19]. In par-
ticular, miRNAs secreted by cancer cells are packed into extracellular vesicles (EVs) and
released into peripheral blood. EVs are largely involved in the cross-talk between cancer
cells and the microenvironment [20,21]. The important involvement of EVs and miRNA
in ontogenetic processes and their availability in biological fluids, make these molecules
optimal biomarkers in oncology [20,22].
This review summarizes the main miRNAs involved in HER2-positive BC tumorigen-
esis, focusing on their prognostic and predictive role.
2. Extracellular Vesicles and MicroRNAs
EVs are small lipid bilayer-delimited particles that are naturally released by cells and
involved in cell communication [23]. EVs can be detected in biological fluids such as serum,
plasma, urine, saliva, breast milk, bile, amniotic fluid, and cerebrospinal fluid [24,25]. Once
released into the extracellular fluid, EVs may link to the cell plasma membrane, fusing
directly with the membrane or being endocytosed, resulting in delivery of proteins and
RNA into the target cell [24]. EVs are involved in several biological processes such as
antigen presentation, immune regulation, apoptosis evasion, drug resistance, and angio-
genesis [25–28]. Based on their size, they are classified into apoptotic bodies (50–5000 nm)
released by apoptotic cells, shedding microvesicles/ectosomes (100–1000 nm) produced
by budding from the plasma membrane, and exosomes (30–150 nm) that originate from
intracellular multivesicular bodies and are secreted in the extracellular space upon fusion
with the plasma membrane [20,23,29]. They carry proteins, metabolites, lipids, mRNA,
miRNA, long-non-coding RNA, and DNA [24–26,30,31]. A large body of evidence suggests
that cancer cells release a higher amount of EVs compared to non-malignant cells [25,26].
The most common methods reported for isolating exosomes from serum or plasma are
commercial kits available for the isolation of EVs the size of exosomes (e.g., Total Exosomes
Isolation Kit—Invitrogen) [29]. Exosomes contain miRNAs that are strongly involved in
the cross-talk between cancer cells and the microenvironment. miRNAs are short, noncod-
ing, single-stranded RNAs of 21–25 nucleotides, which regulate gene expression at a post
transcriptional level by binding to the 3′untranslated region (3′UTR) of its target messenger
RNA [32]. miRNAs can be present in the peripheral blood or packed into EVs such as
exosomes [29]. MiRNAs are a class of small, noncoding, regulatory RNAs that are involved
in both physiological and pathological processes, such as cancer proliferation. In physiolog-
ical processes, miRNA are produced by non-cancerous cells. The most common techniques
reported for miRNA profiling are: microarray analysis; bead-based flow-cytometric tech-
niques; and real-time PCR, SAGE, or RAKE assay, with peculiar strengths and weaknesses
under investigation [33–37].
3. miRNAs in HER2-Positive Breast Cancer
Several preclinical and clinical studies have focused their attention on the research of
miRNAs linked to HER2 pathways in BC. In most of these cases, miRNAs were isolated
from tumor tissues (cell lines or formalin-fixed paraffin embedded samples). Table 1
summarizes all the miRNAs known to be involved in HER2-positive BC tumorigenesis.
The most widely reported miRNAs in the literature are: miR-155, miR-21, miR-205, and
miR-125 families. In the literature, the most widely cited miRNAs related to HER2-positive
subtypes are the following:
miR-155 has been found upregulated in HER2-positive BC in both early and metastatic
settings [38]. miR-155 has an oncogene function in the interaction with the MAPK pathway
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through constitutive activation of STATs proteins by inhibiting SOCS1 gene and activating
AKT and Src [39,40].
miR-21 is one of the most investigated miRNAs in oncology. It has been found
overexpressed in all BC subtypes, but mainly in the HER2-positive hormone receptors
negative subtype [41,42]. In particular, high expression of miR-21 has been found to
significantly correlate with more aggressive tumor behavior (larger tumor with high nuclear
grade) and poor survival outcomes [43]. In vitro studies have shown that up-regulation
of miR-21 induced by HER2/neu signaling via MAPK (ERK1/2) pathway promotes cell
invasion through downregulation of PDCD4 (programmed cell death 4) [43].
miR-205 has been detected in serum of BC patients with a decreasing expression from
the less aggressive BC subtypes to the more aggressive ones, mainly in HER2-positive
and triple-negative tumors [44,45]. It targets HER3 directly, inhibiting SKBr3 in BC cell
lines [46,47]. Its oncosuppressive role is also linked by EMT suppression [45].
Table 1. HER2-positive breast cancer miRNA expression.
miRNA ExpressionLevel Gene Target
# Action Evidence Sample References
miR-489 down SMAD3, SHP2,HER2
Cell growth, invasion and EMT inhibition
(decreased expression of HER2)
clinical/
preclinical tissue [48]
miR-520d down TWIST1 Restoration of E-cadherine expression(reduction in invasiveness)
clinical/
preclinical tissue [49,50]




SAPK/JNK HER2 downstream inhibiting effect preclinical tissue [53]













miR-181c down OPN Increased HER2-positive signature,enhanced chemosensitivity
clinical/
preclinical tissue [51,57,58]






proliferation inhibition, and apoptosis
clinical/
preclinical tissue [51,60]






































miR-147 down EGFR1, AKT2,CDK4, RB1
EGFR-driven cell-cycle (cell proliferation
inhibition) preclinical tissue [67]
miR-124 down EGFR1, STAT3 Cell growth and differentiation inhibition preclinical tissue [68]
# Gene targets included in the table were identified through an in silico analysis; * HR: hormone receptors; § BC: breast cancer.
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Its downregulation in serum of BC patients compared to healthy people suggests a
possible role as a marker for BC diagnosis [63,64].
miR-125b belongs to the miR-125 family. miR-125b is generated from two genes:
miR-125b-1 (on chromosome 11q24) and miR-125b-2 (on chromosome 21q21). It can be up-
or downregulated depending on the tumor type [69–72]. In BC patients, its upregulation
seems to promote EMT expression with an important implication in metastasis develop-
ment [73]. Other direct targets of miR-125b are the EGFR family genes, mainly ERBB2 and
ERBB3. In particular, in BC cell lines, miR-125b seems to induce a suppression of these
genes [74]. Evidence from paraffin-embedded BC tissue samples reported a significant cor-
relation between miR125b expression and HER2 expression (p < 0.001), with an important
prognostic implication for the patient’s overall survival (OS) [66].
Finally, Lowery et al, through the expression profiling analysis of 453 miRNAs from
formalin-fixed paraffin-embedded samples of 29 early BC patients, using an artificial neural
network (ANN) and RQ-PCR for validation, reported a signature of five miRNAs (miR-
520d, miR-181c, miR-302c, miR-376b, and miR-30e-3p), which seemed to accurately predict
HER2 status in early BC patients [51].
4. Predictive Biomarkers
The identification of biomarkers able to predict treatment sensitivity before any in-
tervention remains one of the main goal for oncologists. Thanks to the easy availability
of miRNAs, they can be an optimal biomarker. Several published papers investigated the
predictive role of miRNAs isolated in both BC tissue and blood. Table 2 summarizes miR-
NAs known to be predictive of chemotherapy or anti-HER2-targeted therapy sensitivity. In
particular, data from different clinical and preclinical studies identified miR-125b, miR21,
miR-210, and miR-155 as predictive biomarkers of trastuzumab resistance. Circulating
miR-125b in blood serum of early BC patients seems to be significantly associated with
neoadjuvant chemotherapy response. In particular, higher expression levels of miR-125b
have been reported in resistant patients compared to responsive ones [75]. Wang et al.
demonstrated an association between higher miR-125b expression and a higher percent-
age of proliferating cells in BC tissue [75]. Biologically, it can be explained by the Bak1
(Bcl-2 antagonist Killer 1) downregulation induced by miR-125b, which suppresses drug
efficacy [76]. BaK1 is also known to be involved in the epithelial–mesenchymal transition
process through EMT dysregulation, resulting in an increased resistance to chemother-
apy [77]. In addition, preclinical evidence has suggested that the upregulation of miR-21
induced trastuzumab resistance due to the reduction of PTEN gene expression [78–80].
Another possible biological mechanism of resistance is PI3K pathway dysregulation by
miR-21 and EMT activation with the triggering of IL-6/STAT3/NF-kB-mediated signal-
ing [81]. A study by Liu et al on circulating miR-21 (ser-mir21) in HER2-positive early BC
patients treated with neoadjuvant chemotherapy plus trastuzumab showed a significant
correlation between changes in ser-miR-21 expression and treatment sensitivity [78]. The
authors reported a significant reduction of expression of ser-miR-21 levels at the end of
the second cycle and at the end of neoadjuvant treatment compared to the baseline value
(before start of treatment), mainly shown in clinical responders (p < 0.001). These results
were confirmed by Rodríguez-Martínez et al., who observed lower levels of miR-21 in
HER2-positive patients during neoadjuvant treatment with trastuzumab [79]. They also
highlighted a significant association between higher levels of exosomal miR-21 and circu-
lating tumor cells [79]. In a study by Jung et al. on plasma samples of BC patients who
underwent neoadjuvant trastuzumab-based chemotherapy, levels of miR-210 inversely
correlated with treatment response. Higher levels of miR-201 have been reported in pa-
tients with residual disease compared to those with pathologically complete response
(p = 0.0359) [82]. An in vitro study confirmed these data, showing a higher expression of
miR-21 in trastuzumab-resistant BT474 cells [82]. miR-155 was identified as a negative pre-
dictive marker too. In a cohort of 175 BC patients, 107 early stage and 68 in the metastatic
setting, the upregulation of miR-155 was related to poor trastuzumab sensitivity [83].
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Table 2. Predictive value for treatment outcomes of miRNAs expressed in HER2-positive early breast cancer.
miRNA ExpressionLevel Gene Target
















miR-205 up EGFR, VEGF-A,HER3, AKT
Increased sensitivity to anti-HER2





Increased sensitivity to anti-HER2
therapy preclinical tissue [61]












miR-30c up TWF1, IL-11,YWHAZ
Increased sensitivity to taxol, doxorubicin
and tamoxifene preclinical tissue [86,87]
miR-26a up CCNE2 Increased sensitivity to trastuzumab preclinical tissue [88]
miR-30b up CCNE2 Increased sensitivity to trastuzumab preclinical tissue [88,89]




5p up ADAM10 Increased sensitivity to trastuzumab clinical tissue [65]
miR-23b-






Trastuzumab resistance preclinical tissue [91]
miR-656-
5p down CREB1 Trastuzumab resistance preclinical tissue [91]
miR-340-
5p down C-MET Trastuzumab resistance preclinical tissue [91]
miR-770-
5p up PI3K, MAPK Potentiated trastuzumab effect preclinical tissue [92]
miR-200b up PTEN Trastuzumab resistance preclinical/clinical
tissue/
blood [93]
miR-135b up CyclinD2 Increased sensitivity to trastuzumab preclinical/clinical
tissue/
blood [93,94]
miR-29a up IGF-1R, PTEN Trastuzumab and adryamicin resistance preclinical/clinical
tissue/
blood [95,96]
miR-141 down ERBB4 Trastuzumab resistance preclinical tissue [97]
miR-148 up MAPK/ERK(ERBB3 genes) Increased pathological complete response clinical blood [98]
miR-155 up SOCS1,STAT3 Trastuzumab resistance preclinical/clinical
tissue/
blood [39,83]
miR-221 up PTEN Trastuzumab resistance preclinical tissue [99]
# Gene targets included in the table were identified through an in silico analysis.
On the contrary, miR-148a-3p and miR-205 seem to be positive predictive biomarkers
for anti-HER2-targeted therapies. In particular, the early blood detection of miR-148a-3p
seems to identify early responsive patients to neoadjuvant anti-HER2 treatments [100].
Indeed, the study by Di Cosimo et al. demonstrated a strong correlation between miR-
148a-3p and a pathologically complete response in a BC population treated with primary
trastuzumab (p = 0.008) [100]. Consistently, in vitro studies reported that miR-148a over-
expression inhibits BC cell proliferation through inhibition of the MAPK/ERK signaling
pathways by direct targeting of ERBB3 genes and angiogenesis inhibition [98]. Preclinical
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evidence has shown how the miR-205 restores a pro-apoptotic activity. In BC tissues,
miR-205 directly targets HER3 receptor and inhibits the AKT-mediated survival pathway,
increasing the responsiveness to both tyrosine kinase inhibitors (such as Lapatinb and
Gefitinb) and trastuzumab [47,101]. Finally, a recent preclinical study showed a significant
dysregulation of four miRNAs (miR-23b-3p, miR-195-5p, miR-656-5p, miR-340-5p) in HER2-
positive BC-resistant BT-474 cells, suggesting potential involvement of these miRNAs in
trastuzumab resistance mechanisms [91].
5. Prognostic Biomarkers
As well as the predictive role of miRNAs being widely investigated, their prognostic
value has also been studied (Table 3). The most widely reported miRNAs as negative prog-
nostic biomarkers are: miR-21, miR-155, miR-150-5p, and miR-4734. miR-21 demonstrated
an important prognostic role in HER2-positive early BC patients receiving neoadjuvant
chemotherapy combined with trastuzumab [78]. In particular, Liu et al. demonstrated a
better OS and disease-free survival (DFS) in patients with decreased ser-miR-21 from the
start to the end of neoadjuvant treatment [78]. Higher levels seemed to be associated with
larger tumor size and high Ki67 expression, with a statistically significant correlation with
higher stage (p = 0.008) and tumor grade (p = 0.005). In particular, HER2-positive BC sub-
type (p = 0.002) and negative estrogen receptor cancer (p = 0.002) had a significantly higher
expression of miR-21 [41]. Moreover, in a study on serum samples from 127 patients with
early HER2-positive BC undergoing neoadjuvant treatment, increased levels of circulating
miR-21 before and after chemotherapy showed a significant association with poor OS [84].
In early BC, higher miR-155 expression showed a strong correlation with poor event-free
survival too, in univariate and multivariate analyses [83]. Du et al. identified two intra-
cellular miRNAs, miR-150-5p and miR-4734, as reliable prognostic biomarkers predicting
development of recurrence disease in HER2-positive BC after adjuvant trastuzumab-based
treatment [102].
Contrasting clinical roles have been reported for miR-125. In particular, miR-125-b
was identified as a negative prognostic factor, associated with worse OS in HER2-positive
BC patients [66]. On the contrary, miR-125a-5p was a positive prognostic factor. A low
expression level was found in the serum of patients with shorter survival compared to long-
term patients. It also had a negative correlation with tumor grade (p = 0.004), lymph-node
status (p = 0.004), and tumor size (p < 0.001). [103].
Both miR-205 and miR-148a seem to be positive prognostic factors. In a clinical study
on 52 HER2-positive BC patients treated with adjuvant trastuzumab, miR-205 expression
on sample tissues significantly correlated to better DFS (p = 0.00168) [101]. In addition,
in cell lines, lower levels of miR-205 were correlated to high histological grade biopsies
and higher invasion rate [104]. In preclinical evidence, miR-148a inhibits BC cell migration
and invasion, through wnt-βcatenin pathway inhibition [105] and MMP-13 downregula-
tion [106], resulting in a pro-apoptotic activity [107]. Among positive prognostic factors,
miR-145 has been reported by Quan et al. as downregulated in tumor samples more than
in paracancerous tissue [108]. In agreement with its oncosuppressive function, higher
miR-145 levels seem to be associated with a better survival rate than the lower expression
group (p < 0.028) [48,108].
As expected, due to the close connection between predictive and prognostic value,
some miRNAs overlap between Tables 1 and 2, specifically, miR-210, miR-205, miR-
21, miR-125b, and miR-148. High expression levels of miR-210, miR-21, and miR-125b
correlate to trastuzumab and/or chemotherapy resistance and to poor survival,
accordingly [66,75,78,82,84]. On the contrary, high expression of miR-205 and miR-148
correlated to an increase in sensitivity to cytotoxic treatments and a higher number of
pathologically complete responses at the end of the neoadjuvant therapy, with an improve-
ment in OS [104–107].
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Table 3. Prognostic value of miRNAs expressed in HER2-positive early breast cancer.
miRNA ExpressionLevel Pos/Neg Action Evidence Sample References
miR-21 up neg
Reduction during treatment: better OS and






miR-122 up neg Circulating higher levels associatedwith metastasis clinical
tissue/
blood [54,109]
miR-155 up neg High levels predicts poor eventfree/progression free survival clinical blood [83]
miR-205 up pos
Low level associated with worse prognosis
(high level in high histological grade and
invasion rate)
preclinical tissue [104]
miR-30a up pos Low level associated with higher grade andTNM stage clinical tissue [110]
miR-210 UP neg Reduced RFS preclinical blood [84]
miR-125b up neg Worse OS clinical tissue [66]
miR-125a-
5p up pos
Low levels associated with poor survival,






miR-10b up neg Correlation with tumor stage and lymphnode positivity
preclinical/
clinical tissue [111,112]
miR-373 up neg Correlation with advanced clinical stage preclinical tissue/blood [84,113]
miR-148a up pos Migration and invasion cancer cell inhibition(pro-apoptotic function) preclinical tissue [105–107]
miR-145 up pos Low levels correlate with poorsurvival outcomes
preclinical/
clinical tissue [108,114,115]
miR-4734 up neg Disease recurrence (ERBB2 amplification) preclinical/clinical tissue [102,116]
miR-150-5p up neg Disease recurrence (enhanced cellproliferation, invasion, and migration)
preclinical/
clinical tissue [102,117]
miR-489 down neg Low level correlates with shorter OS clinical blood [118]
miR-770-5p up pos Cell invasion and motility inhibition preclinical tissue [92]




Emerging evidence highlights the key role in cell-to-cell communication and tumori-
genesis of miRNAs. Due to their easy availability in blood and tumor tissue, they represent
the optimal biomarker in oncology. Actually, a great deal of effort has been put into basic
and clinical research to isolate a signature of miRNAs with predictive and prognostic
value. This issue is particularly important in patients treated with targeted therapies,
such as HER2-positive BC therapies. Data from our review identified a panel of miRNAs
expressed in HER2-positive BC potentially able to predict treatment and survival outcomes.
Unfortunately, available data are not enough to define whether some miRNAs are better
predictors than others. In the available studies, the miRNA level changes were evaluated
in different ways, using fold change in some cases and p-value in others, which made
a comparison between the studies difficult. Moreover, further investigations would be
necessary to properly define and validate these molecular tools as clinical biomarkers.
Despite this, our literature review identified a triplet of miRNAs (155, 125b, 21), typically
expressed in HER2-positive BC, that seem to be valid negative predictive and prognostic
biomarkers. Available evidence is promising but requires further data from clinical trials. A
future development could be the periodic assessment of a panel of HER2-specific miRNAs
in patients on neoadjuvant treatment to enable early prediction of treatment resistance and
to tailor patient management.
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